VEGFA and laryngotracheoesophageal cleft: Patients are increasingly receiving Atezo/Bev combination immunotherapy‐based regimens, which pose a bleeding risk due to the inhibition of the VEGF pathway by bevacizumab, along with expanding their indications for unresectable HCC and advanced LC.8, 9